Connect your AI

Opus Genetics IRD Reclassification Of Warrant Liabilities To Equity Upon Exercise

Reclassification Of Warrant Liabilities To Equity Upon Exercise at other companies

IonQIONQ

$7.14M-34.8%

CoreWeave, Inc. CRWV

$0-100%

PureCycle Technologies, Inc.PCT

$81K—

Jade Biosciences, Inc. Common StockJBIO

$2.79M—

HTF

Heartflow, Inc. Common StockHTFL

$16.18M—

Eve HoldingEVEX

$631.75K—

Other financials

Income statement

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

Operating cash flow-$12.7M-41.5%

Valuation

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept ird:ReclassificationOfWarrantLiabilitiesToEquityUponExercise.

The official record: Opus Genetics’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's reclassification of warrant liabilities to equity upon exercise.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Opus Genetics's reclassification of warrant liabilities to equity upon exercise?: Opus Genetics (IRD) reported reclassification of warrant liabilities to equity upon exercise of $263K in Q4 2025.
What does reclassification of warrant liabilities to equity upon exercise mean?: Reflects the non-cash accounting adjustment made when warrant liabilities are settled or exercised and moved from the liability section to shareholders' equity. This indicates a reduction in financial risk as the company's obligation to settle warrants in cash or variable shares is extinguished.